Immunotherapy in Myeloma: A Theme Issue in Honor of Prof. Dr. Gösta Gahrton
1
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
2
Service d′Hématologie, Hôpital Pitié Salpêtrière, 47–83 Boulevard de L′hôpital, F-75013 Paris, France
*
Author to whom correspondence should be addressed.
Hemato 2022, 3(1), 1-2; https://doi.org/10.3390/hemato3010001
Submission received: 13 December 2021
/
Accepted: 13 December 2021
/
Published: 22 December 2021
(This article belongs to the Special Issue Immunotherapy in Myeloma: A Theme Issue in Honor of Prof. Dr. Gösta Gahrton)
Immunotherapy has become a major pillar in the treatment of multiple myeloma. This Special Issue of Hemato addresses the increasing role of immunotherapy-based treatment options in multiple myeloma and is dedicated to Prof. Gösta Gahrton, former president of the European Society for Blood and Marrow Transplantation (EBMT), who, in 1987, published results of allogeneic stem cell transplantation as one of the most effective immunotherapies in patients with multiple myeloma [1]. Even if allogeneic stem cell transplantation has not found its definitive role in the treatment of multiple myeloma, our understanding of the immunological interaction of myeloma cells and the microenvironment and the improving techniques of monoclonal or bispecific antibodies and CAR-T technology as well as translational research on myeloma has rapidly developed in the last 30 years and immunotherapy has become a major backbone in the treatment of multiple myeloma.
After a personal introduction to Prof. Gahrton by Per Ljungman, Juan Luis Reguera-Ortega from José A. Pérez-Simón’s group in Sevilla presents an overview of the rapidly growing field of chimeric antigen receptor T-cells (CAR-T) in myeloma [2], before Nico Gagelmann, from the Hamburg group, summarizes the effect of donor T-cells (DLI) after allogeneic stem cell transplantation to enhance the graft-versus-myeloma effect [3]. The increasing role of natural killer cells is highlighted and reviewed by Marie Therese Rubio, Adèle Dhuyser, and Stéphanie Nguyen from Nancy [4].
The development of monoclonal, bispecific, and immune conjugated antibodies is described by Christie Verkleij, Wassilis Bruins, Sonja Zweegman, and Niels van de Donk from Amsterdam [5], while Benedetto Bruno together with Giuseppe Lia, Francesca Bonifazi, and Luisa Giaccone describe the development and progress in allogeneic stem cell transplantation for myeloma in the last decades [6]. This Special Issue closes with an article by Luis Gerardo Rodríguez-Lobato from Joan Bladé’s group in Barcelona summarizing the current knowledge about the failure of immunotherapy in multiple myeloma [7].
All the contributions are excellent state-of-the-art studies and the editors express their deep gratitude to the authors and hope that readers will enjoy this Special Issue on this exciting field in the treatment of multiple myeloma.
Funding
This research received no external funding.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Gahrton, G.; Tura, S.; Flesch, M.; Gratwohl, A.; Gravett, P.; Lucarelli, G.; Michallet, M.; Reiffers, J.; Ringdén, O.; van Lint, M.T.; et al. Transplantation in Multiple Myeloma: Report from the European Cooperative Group for Bone Marrow Transplantation. Blood 1987, 4, 1262–1264. [Google Scholar] [CrossRef] [Green Version]
- Reguera-Ortega, J.L.; García-Guerrero, E.; Pérez-Simón, J.A. Current Status of CAR-T Cell Therapy in Multiple Myeloma. Hemato 2021, 2, 660–671. [Google Scholar] [CrossRef]
- Gagelmann, N.; Kröger, N. Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect. Hemato 2021, 2, 207–216. [Google Scholar] [CrossRef]
- Rubio, M.T.; Dhuyser, A.; Nguyen, S. Role and Modulation of NK Cells in Multiple Myeloma. Hemato 2021, 2, 167–181. [Google Scholar] [CrossRef]
- Verkleij, C.P.M.; Bruins, W.S.C.; Zweegman, S.; van de Donk, N.W.C.J. Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates. Hemato 2021, 2, 116–130. [Google Scholar] [CrossRef]
- Bruno, B.; Lia, G.; Bonifazi, F.; Giaccone, L. Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma. Hemato 2021, 2, 89–102. [Google Scholar] [CrossRef]
- Rodríguez-Lobato, L.G.; Oliver-Caldés, A.; Moreno, D.F.; Fernández de Larrea, C.; Bladé, J. Why Immunotherapy Fails in Multiple Myeloma. Hemato 2021, 2, 1–42. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Kröger, N.; Garderet, L. Immunotherapy in Myeloma: A Theme Issue in Honor of Prof. Dr. Gösta Gahrton. Hemato 2022, 3, 1-2. https://doi.org/10.3390/hemato3010001
AMA Style
Kröger N, Garderet L. Immunotherapy in Myeloma: A Theme Issue in Honor of Prof. Dr. Gösta Gahrton. Hemato. 2022; 3(1):1-2. https://doi.org/10.3390/hemato3010001
Chicago/Turabian StyleKröger, Nicolaus, and Laurent Garderet. 2022. "Immunotherapy in Myeloma: A Theme Issue in Honor of Prof. Dr. Gösta Gahrton" Hemato 3, no. 1: 1-2. https://doi.org/10.3390/hemato3010001
APA StyleKröger, N., & Garderet, L. (2022). Immunotherapy in Myeloma: A Theme Issue in Honor of Prof. Dr. Gösta Gahrton. Hemato, 3(1), 1-2. https://doi.org/10.3390/hemato3010001
